Perspective Therapeutics Inc
CATX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$87.84M
Close$
$0.37
68.8% downside
Current Fair Value
68.8% downsideOvervalued by 68.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $87.84 Million |
|---|---|
| Enterprise Value | $68.32 Million |
| Earnings per Share | $-1.4 |
| Beta | 1.85 |
| Outstanding Shares | 73,813,000 |
Return
| Return on Equity | -35.95% |
|---|---|
| Return on Assets | -29.70% |
| Return on Invested Capital | -22.32% |
Valuation & Multiples
| P/E Ratio | -1.03 |
|---|---|
| PEG | 3.1 |
| Price to Sales | - |
| Price to Book Ratio | 0.3 |
| Enterprise Value to Revenue | 186.65 |
| Enterprise Value to EBIT | -0.86 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.42 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.27
Consensus analyst estimateRevenue Estimate
$90,528
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.24
Consensus analyst estimateRevenue Estimate
$56,499
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Perspective Therapeutics Inc
64 employees
CEO: Lori Woods
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.